Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Acrivon Therapeutics, Inc

Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Announces $130 Million Private Placement Financing
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.